An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials (CONNEX-X).

Published: 26-04-2022
Last updated: 14-09-2024

This study has been transitioned to CTIS with ID 2024-511560-93-00 check the CTIS register for the current data. The objective of this trial is to collect additional safety data.The further objective of this trial is to collect long-term efficacy...

Ethical review	Approved WMO
Status	Pending
Health condition type	Schizophrenia and other psychotic disorders
Study type	Interventional

Summary

ID

NL-OMON53746

Source
ToetsingOnline

Brief title
CONNEX-X

Condition

- Schizophrenia and other psychotic disorders

Synonym
Cognitive impairment associated with schiophrenia, Schizophrenia

Research involving
Human

Sponsors and support

Primary sponsor: Boehringer Ingelheim
Source(s) of monetary or material Support: Boehringer Ingelheim

Intervention

Keyword: BI 425809, Cognition, Iclepertin, Schizophrenia

Outcome measures

Primary outcome

The primary endpoint is the occurrence of treatment emergent adverse events

(TEAEs) throughout the extension study.

Secondary outcome

The secondary endpoints are:

- Change from baseline in Clinical Global Impressions-Severity (CGI-S) to end

of treatment (EOT).

- Change from baseline in Hb to EOT.

Further endpoints regarding safety, efficacy and PK are documented in CTP v3.0,

pages 27-28.

Study description

Background summary

Schizophrenia is a serious and chronic mental illness leading to poor quality of life and disability.
The CONNEX programme studies the safety and efficacy of Iclepertin in schizophrenia patients over 26 weeks of treatment.
This extension study makes sure participants that benefit from the study drug can continue treatment (or start active treatment if they received placebo

before) and additional safety information will be collected over this period.

Study objective

This study has been transitioned to CTIS with ID 2024-511560-93-00 check the CTIS register for the current data.

The objective of this trial is to collect additional safety data.

The further objective of this trial is to collect long-term efficacy measures as well as to assess the treatment effect on:
- disability and productivity
- functional impairment
- health-related quality of life
- global impression for both the patient and caregiver burden

Study design

Multi-center, multi-national, open label, single arm extension trial.

Intervention

Once daily 10 mg Iclepertin. Treatment duration is 52 weeks.

Study burden and risks

The amount of visits to the hospital is likely more often than the patient is used to. Additionally, the visits are longer and additional tests are being performed/additional blood is being drawn. Study-specific questionnaires and assessments are also done. These can be experienced as intensive, confronting and/or long.

Earlier trials show that the study drug is generally safe and well tolerated. No serious adverse events have been seen. However, this remains an experimental drug, and there is always a chance of adverse effects we have not seen yet, or worse than we have seen until now. Furthermore, from earlier trials it seems that Iclepertin has a positive effect on cognition, which should lead to an improvement in day-to-day functioning.

Contacts

Public
Boehringer Ingelheim

Basisweg 10
Amsterdam 1043 AP
NL
Scientific
Boehringer Ingelheim

Basisweg 10
Amsterdam 1043 AP
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)

Inclusion criteria

1. Signed and dated written informed consent in accordance with ICH Harmonized Tripartite Guideline for Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial (Visit 1).
2. Clinically stable outpatients who have been diagnosed with schizophrenia (as per Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5)).
3. Patients, who completed 26 weeks of treatment in the parent trial, must enter the extension trial within:
• Within 2 weeks after the end of treatment visit in 1346-0011, 1346-0013 (i.e. Follow Up 1 timepoint including the applicable time windows).
• At the end of safety follow up in 1346-0012 (within 7 days of visit Follow Up 6).
4. Women of childbearning potential (WOCBP) must be ready and able to use highly effective methods of birth control per Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals (ICH M3 (R2)) that result in a low failure rate of less than 1% per year when used consistently and correctly. Such methods should be used throughout the trial, and for a period of at least 35 days after last trial drug intake, and the patient must agree to periodic pregnancy testing during participation in the trial.

5. Have a study partner, defined as any person capable of understanding trial related procedures, with a minimum of 8th grade level of education, who knows the patient well, has been capable of interacting with the patient on regular basis (at least once a week, either private or professional). Study partner does not need to attend visits with the patient but must be reachable by phone. Study partner should preferably be the same person throughout the study, if possible
• Professional study partner (e.g. study nurse, social worker etc.) are allowed if not involved in administering any of the protocol assessments.

Exclusion criteria

1. Participant who developed DSM5 diagnosis other than Schizophrenia or any condition that would prevent the patient from participating in the extension trial (e.g. stroke, head trauma, developed dementia, severe uncontrolled movement disorders or other significant condition since enrolment into the parent phase III trial).
2. Any suicidal behavior and/ or suicidal ideation of type 5 based on the C-SSRS in parent trial and up to and including Visit 1 of this study.
o Patients with Suicidal Ideation type 4 in the C-SSRS (active suicidal thought with intent but without specific plan), in the past 3 months prior to and including Visit 1, can be entered in the study, if assessed and documented by a licensed mental health professional that there is no immediate risk of suicide.
3. Patients diagnosed with moderate or severe substance use disorder (other than caffeine and nicotine), as defined in DSM-5 while the patient was in parent trial and prior to Visit 1 of this study.
4. Positive urine drug screen >= 3 times during the parent trial based on central lab test.
5. Patients who are currently or wish to participate in another investigational drug trial.
6. Any clinically significant finding in the judgment of the investigator such as :
o Clinically significant finding on he Physical examination and/or ECG from the last assessment done in the parent trial.
o Vital signs (including blood pressure (BP) and pulse rate (PR)) that would jeopardize the patient*s safety while participating in the trial or their capability to participate in the trial.
o Symptomatic/unstable/uncontrolled or clinically relevant concomitant disease or any other clinical condition that would jeopardize the patient*s safety while participating in the trial or capability to participate in the trial.
o Significant or unstable physical condition that may require change in medication or hospitalization that would impact cognitive function.
7. Any significant central lab findings based on the last available lab result received during the parent trial such as:
o Severe renal impairment defined as an eGFR < 30mL/min/1.73m^2,

o Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 times upper limit or normal or
o Hb drop below 100g/L (10g/dL) OR Hb decrease of 25% or more from baseline and is below lower limit of normal in parent trial (alert 3 from last measure Hb in parental trial)
o Patients who meet any of the withdrawal criteria before planned end of treatment (26 weeks) in parent trial.
8. Patients who have been diagnosed with hemoglobinopathies during the parent trial.
9. Patients with known ongoing severe or serious infection with SARS-CoV-2.
10. Known history of HIV and/or known on-going Hepatitis B or C infections. As well as any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix.
11. Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
12. Patients with an allergy to BI 425809 and/or any of the excipients (including serious lactose intolerance).
13. Patients who are currently treated or expected to be treated with any of the following: strong or moderate CYP3A4 inhibitors, strong or moderate CYP3A4 inducers, CYP3A4 sensitive substrates,. including grapefruit juice ad St. John*s wort (Hypericum perforatum) and substrates with a narrow therapeutic range (e.g., fentanyl, cyclosporine).

Study design

Design

Study type: Interventional

Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Pending
Start date (anticipated):	02-09-2024
Enrollment:	6
Type:	Anticipated

Medical products/devices used

Registration:	No
Product type:	Medicine
Brand name:	Not applicable
Generic name:	Iclepertin

Ethics review

Approved WMO Date:	26-04-2022
Application type:	First submission
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	02-11-2022
Application type:	First submission
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	25-02-2023
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	01-05-2023
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	05-05-2023
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	12-05-2023
Application type:	Amendment

Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	01-09-2023
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	13-09-2023
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	29-09-2023
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	01-02-2024
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	07-02-2024
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	15-02-2024
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EU-CTR	CTIS2024-511560-93-00
EudraCT	EUCTR2020-003745-11-NL
CCMO	NL80277.100.22